We’re not just consultants — we’re strategic partners guiding regulated health innovation from concept to global launch. Innovenn and its human factors division, Improvita, specialize in helping life science companies develop, validate, and launch complex regulated products — including Software as a Medical Device (SaMD), digital diagnostics, combination products, and drug-device platforms. With deep expertise across regulatory strategy, human factors engineering, clinical validation, and digital product development, we support innovators from early-stage design through submission and post-market success. Our team brings over 250 years of combined experience navigating U.S. FDA, EU MDR, and UK MHRA pathways, designing human-centered studies, and integrating risk-based evidence strategies that accelerate approvals and ensure patient safety. Our specialties include: • Global Regulatory Strategy (FDA, EU MDR, UK MHRA) • SaMD & Digital Health Compliance • Regulatory-Ready Human Factors & Usability Engineering • Clinical Evaluation & Validation for SaMD, Devices & Combination Products • AI/ML & Clinical Decision Support System (CDS) Planning • Lifecycle Submission Support (IDE, 510(k), De Novo, CE Mark) • UX & Patient-Centered Design for MedTech • Evidence Strategy & Risk Management Integration We collaborate with global pharma, medtech startups, and digital health ventures to bring breakthrough products to life — faster, safer, and smarter.
Looking for a particular Innovenn employee's phone or email?
The Innovenn annual revenue was $2 million in 2026.
Mary Dixon is the CEO and Founder of Innovenn.
17 people are employed at Innovenn.
Innovenn is based in Madison, Wisconsin.
The NAICS codes for Innovenn are [32, 3254, 32541, 325].
The SIC codes for Innovenn are [283, 28].